Trial Profile
Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PROGRESS
- Sponsors Roche
- 26 May 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 04 May 2010 Results have been presented at Digestive Disease Week (DDW) 2010.
- 18 Apr 2010 Results presented at the 45th Annual Meeting of the European Association for the Study of the Liver.